Butyrate Gut Health Meta-analysis: What the Evidence Says

Quick Answer

Butyrate Gut Health Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Reduced SCFA production is consistently observed in metabolic and inflammatory disorders, whereas interventions that increase SCFAs improve metabolic outcomes in both animal and human studies. [Alshatari Sumaya (2026); evidence level 1]
• Epidemiological studies link higher polyphenol intake to reduced risk of chronic diseases, traditionally attributed to antioxidant and anti-inflammatory properties. [Alshatari Sumaya (2026); evidence level 1]
• SCFA status has been reported to be associated with many disease states, including metabolic, inflammatory, and oncological disease, with reported health benefits reported with supplementation in humans. [Thakur Devika (2026); evidence level 1]
• While traditional risk factors such as diabetes and hypertension are well-established, recent research has increasingly focused on the "gut-kidney axis," a bidirectional communication network where gut dysbiosis acts not merely as a consequence of renal decline but as a significant driver of disease progression. [Thakur Devika (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For butyrate gut health meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Alshatari Sumaya (2026). Effects of Polyphenol Supplementation on Gut Microbiota Composition and Fecal Short-Chain Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. DOI: 10.3390/nu18111762. PMCID: PMC13258798. PMID: 42280405. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258798/
• Thakur Devika (2026). Circulating Short-Chain Fatty Acid Levels in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. DOI: 10.3390/nu18091440. PMCID: PMC13164688. PMID: 42124048. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164688/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.